Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi-301 phase 2 study of tarlatamab in relapsed/refractory small cell lung cancer
2024-511837-37-00Phase 2Authorised
- Sponsor
- Amgen
- Start
- Dec 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 17
01
Overview
Phase 2, open-label, single-arm trial of tarlatamab in small cell lung cancer (SCLC), sponsored by Amgen. Planned start Dec 2021; status: authorised.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2024-511837-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511837-37-00.